Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Tamponade | 2 | 2015 | 11 | 1.010 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2015 | 33 | 1.010 |
Why?
|
| Pericardial Effusion | 2 | 2015 | 15 | 1.010 |
Why?
|
| Heart Conduction System | 2 | 2015 | 119 | 0.950 |
Why?
|
| Hypertension, Pulmonary | 4 | 2021 | 232 | 0.910 |
Why?
|
| Electrocardiography | 2 | 2015 | 601 | 0.840 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 25 | 0.680 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 31 | 0.680 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2018 | 117 | 0.670 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2016 | 9 | 0.670 |
Why?
|
| Cysts | 2 | 2016 | 70 | 0.630 |
Why?
|
| Heart Defects, Congenital | 1 | 2022 | 596 | 0.580 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2016 | 82 | 0.520 |
Why?
|
| Sirolimus | 1 | 2016 | 118 | 0.500 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 75 | 0.480 |
Why?
|
| Neoplasms | 2 | 2015 | 1667 | 0.460 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2013 | 3 | 0.440 |
Why?
|
| Pneumonectomy | 1 | 2013 | 79 | 0.440 |
Why?
|
| Scleroderma, Systemic | 1 | 2017 | 446 | 0.440 |
Why?
|
| Multiple Organ Failure | 1 | 2013 | 36 | 0.430 |
Why?
|
| Pulmonary Emphysema | 1 | 2013 | 71 | 0.430 |
Why?
|
| Bronchoscopy | 1 | 2013 | 147 | 0.400 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 839 | 0.400 |
Why?
|
| Quality of Life | 4 | 2022 | 1515 | 0.380 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2022 | 110 | 0.360 |
Why?
|
| Familial Primary Pulmonary Hypertension | 2 | 2022 | 25 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 1173 | 0.350 |
Why?
|
| Pleural Effusion | 2 | 2017 | 74 | 0.270 |
Why?
|
| Forced Expiratory Volume | 2 | 2016 | 87 | 0.250 |
Why?
|
| Dyspnea | 2 | 2022 | 87 | 0.250 |
Why?
|
| Humans | 16 | 2022 | 68618 | 0.220 |
Why?
|
| Female | 10 | 2022 | 38074 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2016 | 2324 | 0.200 |
Why?
|
| Male | 10 | 2021 | 37321 | 0.200 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.190 |
Why?
|
| Epoprostenol | 1 | 2021 | 71 | 0.190 |
Why?
|
| Lung | 2 | 2016 | 849 | 0.180 |
Why?
|
| Middle Aged | 7 | 2021 | 21147 | 0.180 |
Why?
|
| Oxygen | 1 | 2022 | 386 | 0.180 |
Why?
|
| Adult | 6 | 2021 | 21403 | 0.170 |
Why?
|
| Lung Volume Measurements | 2 | 2016 | 19 | 0.170 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2018 | 1 | 0.160 |
Why?
|
| SOXF Transcription Factors | 1 | 2018 | 2 | 0.160 |
Why?
|
| HLA-DP beta-Chains | 1 | 2018 | 4 | 0.160 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2018 | 25 | 0.160 |
Why?
|
| Aged | 5 | 2021 | 14862 | 0.150 |
Why?
|
| Kidney | 2 | 2019 | 945 | 0.150 |
Why?
|
| Urinoma | 1 | 2017 | 2 | 0.150 |
Why?
|
| Hydronephrosis | 1 | 2017 | 12 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2016 | 3705 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 365 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 498 | 0.140 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 103 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 253 | 0.130 |
Why?
|
| Pulmonary Ventilation | 1 | 2016 | 28 | 0.130 |
Why?
|
| United States | 2 | 2019 | 7367 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 4848 | 0.120 |
Why?
|
| Manometry | 1 | 2016 | 276 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 419 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2016 | 453 | 0.120 |
Why?
|
| Echocardiography | 1 | 2017 | 515 | 0.120 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 27 | 0.110 |
Why?
|
| Action Potentials | 1 | 2015 | 223 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2017 | 7277 | 0.110 |
Why?
|
| South Carolina | 2 | 2017 | 2752 | 0.110 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.110 |
Why?
|
| Blood Viscosity | 1 | 2013 | 9 | 0.110 |
Why?
|
| Plasmapheresis | 1 | 2013 | 18 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2015 | 880 | 0.100 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1054 | 0.100 |
Why?
|
| Triglycerides | 1 | 2013 | 184 | 0.100 |
Why?
|
| Logistic Models | 1 | 2015 | 1420 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1465 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2279 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2022 | 7029 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3259 | 0.070 |
Why?
|
| Risk Factors | 1 | 2015 | 5731 | 0.060 |
Why?
|
| Young Adult | 1 | 2015 | 5717 | 0.060 |
Why?
|
| Adolescent | 1 | 2015 | 8912 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2021 | 35 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 187 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 319 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 136 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 19 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2018 | 220 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 240 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1056 | 0.040 |
Why?
|
| Exudates and Transudates | 1 | 2017 | 25 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.040 |
Why?
|
| New York | 1 | 2017 | 223 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1738 | 0.040 |
Why?
|
| Thoracentesis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 627 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1619 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1140 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 47 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 786 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 2007 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2689 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1196 | 0.020 |
Why?
|